Nortriptyline in depressed patients with left ventricular impairment

Area of Science:

• Cardiology
• Psychiatry
• Pharmacology

Background:

• Tricyclic antidepressants (TCAs) effects on cardiac function in patients with ventricular impairment are under-researched.
• Imipramine hydrochloride, a TCA, showed no impact on ejection fraction but was poorly tolerated due to orthostatic hypotension.
• Nortriptyline hydrochloride, another TCA, causes less orthostatic hypotension in patients without heart disease.

Purpose of the Study:

• To evaluate the safety and efficacy of nortriptyline hydrochloride in depressed patients with left ventricular impairment.
• To assess the impact of nortriptyline on ejection fraction and blood pressure in this patient population.

Main Methods:

• 21 depressed patients with left ventricular impairment were enrolled.
• Ejection fraction and blood pressure were measured before and after nortriptyline treatment.
• The incidence of orthostatic hypotension was recorded.

Main Results:

• Nortriptyline treatment did not alter ejection fraction.
• Only one patient (5%) experienced orthostatic hypotension.
• Nortriptyline was well-tolerated by the majority of patients.

Conclusions:

• Nortriptyline hydrochloride is a relatively safe and effective treatment option for depression in patients with left ventricular impairment.
• Nortriptyline offers a favorable safety profile regarding orthostatic hypotension compared to imipramine in this vulnerable population.